Trandolapril is a prodrug that is de-esterified to trandolaprilat. It is believed to exert its antihypertensive effect through the renin-angiotensin-aldosterone system.
CAT No: 10-101-125
CAS No:87679-37-6
Synonyms/Alias:RU 44570; (2S,3aR,7aS)-1-[(S)-N-[(S)-1-Carboxy-3-phenylpropyl] alanyl] hexahydro-2-indolinecarboxylic acid 1-ethyl ester
Trandolapril is a synthetic, non-peptide angiotensin-converting enzyme (ACE) inhibitor widely recognized for its role in modulating the renin-angiotensin system. As a carboxyl-containing prodrug, it undergoes bioactivation to its active diacid form and is structurally characterized by its bicyclic ring system and distinctive side chains, which contribute to its high affinity for ACE. The compound's inhibitory properties make it a valuable tool in the investigation of enzymatic pathways involved in blood pressure regulation, vascular homeostasis, and related biochemical processes. Due to its defined mechanism of action and well-characterized molecular profile, trandolapril has become an important reference compound for researchers studying cardiovascular biochemistry, enzyme kinetics, and drug metabolism.
Enzyme inhibition studies: Trandolapril is extensively used as a reference standard in the study of ACE inhibition, enabling researchers to quantitatively assess the potency and specificity of novel ACE inhibitors. Its well-documented inhibitory profile allows for the benchmarking of new compounds in enzyme assays, supporting structure-activity relationship (SAR) analyses and the elucidation of key molecular interactions within the active site of ACE. By serving as a comparator, it aids in the identification of promising lead compounds in cardiovascular drug discovery.
Pharmacokinetic and metabolic research: As a prodrug, trandolapril provides a model system for investigating hepatic and plasma esterases responsible for prodrug activation. Researchers utilize it to study the conversion rates, metabolic pathways, and distribution profiles of ACE inhibitors, facilitating a deeper understanding of prodrug design and optimization. These studies contribute valuable insights into the factors influencing oral bioavailability, tissue targeting, and elimination kinetics of carboxylester-containing compounds.
Vascular biology and signal transduction: The compound is frequently employed in experimental models to dissect the biochemical pathways underlying vascular tone regulation and endothelial function. By inhibiting ACE, trandolapril modulates levels of angiotensin II and bradykinin, allowing researchers to explore the downstream signaling events involved in vasoconstriction, nitric oxide synthesis, and inflammatory responses. Its use in these contexts supports the investigation of molecular mechanisms that govern vascular homeostasis and dysfunction.
Analytical method development: Trandolapril serves as a standard or internal reference in the development and validation of analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry. Its chemical stability and well-defined chromatographic behavior make it suitable for method calibration, quantitation, and quality control in pharmaceutical and biochemical laboratories. Utilizing this compound in analytical workflows ensures the reliability and reproducibility of quantitative assays for ACE inhibitors and related substances.
Comparative efficacy studies: In preclinical research, trandolapril is often included as a benchmark compound in studies evaluating the efficacy of new ACE inhibitors or alternative agents targeting the renin-angiotensin system. By providing a consistent point of reference, it enables the objective assessment of pharmacodynamic effects, dose-response relationships, and off-target activities. These comparative studies are essential for advancing the development of next-generation cardiovascular modulators and for refining experimental models of enzyme inhibition.
Trandolapril has a favourable pharmacological profile and an antihypertensive efficacy at least comparable to that of other ACE inhibitors. The pharmacological characteristics of trandolapril allow it to provide good 24-hour control of BP with once-daily administration. Trandolapril has also demonstrated some efficacy in a small number of patients with CHF. In addition, trandolapril provides long term protection against all-cause mortality in patients with LV dysfunction after MI. The results of the Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) study will determine its potential as a cardioprotective agent in patients with coronary artery disease and preserved LV function. Thus, trandolapril represents an effective, well-tolerated and convenient treatment option for patients with mild to moderate hypertension or LV systolic dysfunction after MI.
Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders.
Trandolapril is a well known angiotensin converting enzyme (ACE) inhibitor with many cardiovascular (CV) indications. The objectives of this article are to review the pharmacokinetics and pharmacodynamics properties of trandolapril and to focus on its clinical relevance in cardiovascular medicine. Various populations have been studied in large clinical trials including patients with congestive heart failure (CHF) after an acute myocardial infarction (AMI), diabetics, patients with hypertension (HTN), stable coronary artery disease (CAD) and prevention of proteinuria. Long-term treatment with trandolapril in patients with reduced left ventricular function soon after AMI significantly reduced the risk of overall mortality, mortality from CV causes, sudden death, and the development of severe CHF. Treatment with trandolapril after AMI complicated by left ventricular dysfunction appears to be of considerable importance in patients with diabetes mellitus by saving lives and substantially reducing the risk of progression to severe CHF as well. Moreover, trandolapril reduces progression to proteinuria in high-risk patients. Some of the advantages of trandolapril over other ACE inhibitors are the wide spectrum of patient populations studied, the well established dosage and its proven trough-to-peak effect ratios permitting a safe once-a-day administration.
Diaz, A., & Ducharme, A. (2008). Update on the use of trandolapril in the management of cardiovascular disorders. Vascular health and risk management, 4(6), 1147.
2. TMEM16F and dynamins control expansive plasma membrane reservoirs
3. Cationic cell-penetrating peptides are potent furin inhibitors
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More